Page 4 - Pharmaceutical Firms

Mukul Agrawal portfolio pharmaceutical stock surges 10% in weak market

Shares of Neuland Laboratories rallied 10 per cent to ₹13,500 on the BSE in Monday's intra-day trade in otherwise a subdued market.

Wockhardt shares rise 2% after exiting US generics business

Wockhardt shares rose 2 per cent after it decided to exit the US generic pharmaceutical segment after incurring consistent losses

Asston Pharmaceuticals IPO booked 173x; check allotment, GMP, listing date

Asston Pharmaceuticals IPO allotment status: Investors can check their status on the official websites of BSE and Maashitla Securities

Nectar to sell API, formulations and menthol biz to Ceph for ₹1,290 cr

Nectar Lifesciences Ltd on Tuesday said it will sell its active pharmaceutical ingredients and formulation along with menthol business assets to Ceph Lifesciences Pvt Ltd, for Rs 1,290 crore. The company has signed a definitive Business Transfer Agreement (BTA) for the sale of its core business division, comprising the manufacture, distribution, and marketing of Active Pharmaceutical Ingredients (APIs) and formulations to Ceph Lifesciences for Rs 1,270 crore on a slump sale basis, Nectar said in a regulatory filing. Additionally, the company has entered into an Asset Purchase Agreement (APA) for the sale of its menthol business assets to Ceph Lifesciences for Rs 20 crore, marking a comprehensive restructuring move aligned with its future strategy, it added. "By divesting mature segments of our business, we are laying the foundation for a focused and agile organisation geared towards innovation and long-term value creation," Nectar Lifesciences Promoter and Chairman Sanjiv Goyal ...

Are generic medicines as good as branded ones? Here's what you should know

Are cheaper generic medicines really as good as expensive branded ones? Here's what doctors and pharma experts say about quality, safety, and trust

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE

Laurus Labs nears record high after 4 years, zooms 84% from 52-week low

Laurus Labs management sees a clear pathway for further margin expansion as the company continue delivering on mid-late phase projects, ramping up new assets, and better asset utilisation.

Govt, industry hold talk on issues over marketing code for medical devices

Medical device companies raise issues with the DoP over UDMPMD norms related to disclosure of training expenses and restrictions on overseas training approvals

SastaSundar to invest Rs 150 crore in 2 yrs, aims turnaround in FY26

SastaSundar Ventures Ltd is in the process of investing Rs 150 crore over the next two years to strengthen its digital healthcare platform and warehousing infrastructure to make a turnaround and return to profit in FY'26, a company official said on Thursday. The investment will largely be funded through a Rs 145-crore capital pool, created from the Flipkart Health exit settlement and internal treasury income. The Kolkata-based online pharmacy ended its partnership with Flipkart Health earlier this year and relaunched its B2C platform under its own brand. "We are aiming to return to net profit in the current fiscal through strategic initiatives. We are focusing on the execution of these and capital-efficient growth to recover the company from a Rs 122 crore net loss in FY'25. "Out of the Rs 150 crore, about Rs 40 crore was deployed in FY'25, and the remaining Rs 110 crore will be invested in FY'26 and FY'27," SastaSundar Chairman B L Mittal told PTI. To tap into the rising demand f

Pharma manufacturing tends to cause AMR in communities: Nick Voulvoulis

Changes are required both in manufacturing practices as well as in regulatory oversight, says Voulvoulis

Sun Pharma's Halol plant gets 8 USFDA observations post inspection

Drug major Sun Pharma on Saturday said the US health regulator has issued a Form 483 with 8 observations after inspecting its Halol (Gujarat) manufacturing plant. The US Food and Drug Administration (USFDA) conducted a good manufacturing practices (GMP) inspection at the Halol facility from June 2-13 2025, the Mumbai-based drug maker said in a regulatory filing. At the conclusion of the inspection, the USFDA issued a Form-483 with 8 observations, it added. As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine altSonflex1-2-3 in collaboration with GSK

Indian pharma market grows 7.2% in May led by chronic therapies

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches

Concord Biotech share price pops 6% on healthy Q4 nos; profit zooms 48% YoY

Concord Biotech share price rose on the back of a healthy March quarter of financial year 2025 (Q4FY25) results.

Refineries to banks: Here are the sectors that topped investments in FY25

In FY25, sectors like refineries, telecom services, and iron and steel led capital investments in India

Mankind Pharma shares slide 3% as Q4 profit declines; details here

Shares of Mankind Pharma dropped over 3 per cent after it posted a 10 per cent fall in consolidated net profit Q4 FY25

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

IPA and Ind-Ra say Trump's MFN-based drug pricing move will impact innovators more than Indian generics, with CDMO firms likely to gain from offshore cost advantages

India's pharma market grows 7.8% in April, led by chronic therapies

Chronic therapies and price increases drove 7.8 per cent growth in India's pharma market in April 2025, with cardiac and gastrointestinal segments showing double-digit value gains

TPG acquires 35% in SCHOTT Poonawalla, SII retains minority stake

SCHOTT Pharma keeps 50% stake in Indian JV as TPG joins with Novo Holdings to support global pharma supply chain growth; deal expected to close in H1 2025

Ashish Kacholia portfolio stock surges 10% on strong Q4 performance

Share of Ami Organics surged 10% to ₹ 1,243 on the BSE in Friday's intra-day deal, after the company posted 144% YoY jump in its consolidated PAT at ₹ 62.7 crore in Q4FY25.